Community Practice Connections™: 12th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™

Release Date: July 30, 2021
Expiration Date: July 30, 2022

Activity Overview

This Community Practice Connections™ program provides an in-depth review of some of the key highlights from the 12th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies™, held in May 2021. This unique and engaging multimedia activity is ideal for the community-based clinician and focuses on the practical aspects of managing patients with ovarian, cervical, and endometrial cancer, while placing recent clinical trial data into a clinical context. The program is designed for those who did not attend the live meeting and would help to reinforce learnings for those who did.

Acknowledgement of Commercial Support

This educational activity is supported by educational grants from AstraZeneca; Eisai Inc.; Genmab US, Inc; GSK–GlaxoSmithKline; Merck & Company, Inc; R-Pharm US, LLC; and Seagen Inc.

Target Audience

This educational activity is directed toward medical oncologists and fellows who treat patients with gynecologic malignancies. Gynecologic oncologists, surgical oncologists, radiation oncologists, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of gynecologic malignancies will be invited to participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Discuss the current and emerging roles for germline and somatic testing in newly diagnosed and recurrent ovarian cancers.
• Outline current and emerging role of PARP inhibitor therapy in gynecological malignancies with a focus on ovarian cancer.
• Review the rationale supporting the role of immunotherapy in gynecologic malignancies with a focus on cervical and endometrial cancers.
• Integrate recent data and emerging trends into clinical context and analyze their therapeutic implications in the management of gynecologic malignancies.
• Outline evidence-based approaches to mitigate adverse events associated with targeted therapies and immunotherapies in the treatment of patients with gynecologic malignancies

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Faculty

Robert L. Coleman, MD, FACOG, FACS
Gynecologic Oncologist and Chief Scientific Officer
US Oncology Research
The Woodlands, TX

Disclosures: Grant/Research Support: Array BioPharma, AstraZeneca, Clovis Oncology, EMD Serono, Gradalis, Janssen, Merck; Other: Advisory Board: AstraZeneca, Bayer Healthcare, Inc., Caris Life Sciences, Cerulean Pharma, Clovis Oncology, GamaMabs, Janssen, Novocure, Precision Oncology, Roche, Tesaro.

Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Boston, MA

Disclosures: Consultant: AstraZeneca, Merck, NextCure, Novartis.

Bradley J. Monk, MD, FACS, FACOG
Director and Professor
Division of Gynecologic Oncology
Creighton University School of Medicine at St. Joseph’s Hospital and Medical Center
Medical Director, Gynecologic Oncology
Research
US Oncology
Phoenix, AZ

Disclosures: Consultant: AbbVie, Advaxis, Amgen, AstraZeneca, Clovis Oncology, Genmab, GOG Foundation, Gradalis, ImmunoGen, Iovance Biotherapeutics, Karyopharm Therapeutics, Merck, Mersana Therapeutics, Myriad, Novocure, Pfizer, Puma Biotechnology, Roche/Genentech, Sorrento Therapeutics, Takeda, Tesaro, VBL Therapeutics; Speakers’ Bureau: AstraZeneca, Clovis Oncology, Janssen/Johnson & Johnson, Roche/Genentech, Tesaro.

Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshospitalet-Copenhagen University Hospital
Copenhagen, Denmark

Disclosures: Grant/Research Support: Apexigen, AstraZeneca, Boehringer Ingelheim, Clovis Oncology, Pfizer, Tesaro-GSK, Ultimovacs; Consultant: AstraZeneca, Biocad, Clovis Oncology, Geneos, Genmab, GSK, Karyopharm Therapeutics, Merck, Mersana, MSD, Oncology Venture, Pfizer, Roche, Seattle Genetics, Sera Prognostics, Sotio, Takeda, Tesaro, ZaiLab; Stock/Shareholder: Karyopharm Therapeutics, Sera Prognostics; Other: Leadership role: Karyopharm Therapeutics, Sera Prognostics.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.